March 15, 2019
The House Energy and Commerce Health Subcommittee held a legislative hearing examining seven bills related to lowering the cost of prescription drugs. Discussion focused on how to combat patent abuses, including misuse of the Risk Evaluation and Mitigation Strategies system and pay-for-delay settlements. Of note, some Republicans raised concerns about the CREATES Act of 2019, which seeks to end the practice of brand name drug manufacturers withholding samples to prevent generic competition. This legislation has generally enjoyed bipartisan support and was seen as likely for legislative action on prescription drug prices this year. This hearing may have thrown a little cold water on that outlook. Read our hearing summary here.